Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other financing activities (2024)

Lexicon Pharmaceuticals (LXRX) has disclosed Other financing activities for 2 consecutive years, with -$1000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Other financing activities changed N/A to -$1000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$1000.0, a 99.92% increase, with the full-year FY2024 number at -$1.3 million, changed N/A from a year prior.
  • Other financing activities was -$1000.0 for Q4 2024 at Lexicon Pharmaceuticals, up from -$906000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$1000.0 in Q4 2024 to a low of -$906000.0 in Q3 2024.